Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

A 34-year-old woman comes to the clinic for a follow-up visit. Four weeks ago, she was diagnosed with Graves disease and was started on methimazole and propranolol. Today, she reports significant improvement in her symptoms; her palpitations have resolved, and she is sleeping much better. She has not experienced any fever or sore throat. Her blood pressure is 120/75120/75 mm Hg and her pulse is 7272/min. Physical examination reveals a mild, non-tender goiter but no tremors.

Laboratory results from today show:

Laboratory TestResultReference Range
TSH<0.01< 0.01 μ\muU/mL0.4−4.00.4-4.0 μ\muU/mL
Free T41.11.1 ng/dL0.9−1.70.9-1.7 ng/dL
Total T3120120 ng/dL80−20080-200 ng/dL

Which of the following is the most appropriate next step in the management of this patient's antithyroid therapy?

  1. A
    Order a radioactive iodine uptake scan
  2. B
    Add levothyroxine to the current regimen
  3. Maintain the current dose of methimazoleAnswer
  4. D
    Increase the dose of methimazole
  5. E
    Discontinue methimazole and monitor thyroid function

Answer

Maintain the current dose of methimazole
The patient has Graves disease and was started on methimazole 4 weeks ago. She is now clinically euthyroid (resolution of palpitations, normal heart rate) and biochemically euthyroid based on her normal free T4 and total T3 levels. Her TSH remains suppressed, which is a classic and expected physiological response. After initiating treatment for hyperthyroidism, pituitary TSH secretion remains suppressed for several months, even after peripheral thyroid hormone levels (T3 and T4) have completely normalized. Therefore, the most accurate markers for monitoring initial response to antithyroid medications are free T4 and total T3, not TSH. Because her peripheral hormone levels are now within the normal range and she is asymptomatic, the current dose of methimazole is appropriate and should be maintained.

Step-by-Step Solution

1
Evaluate the patient's clinical status after 4 weeks of antithyroid therapy.
The patient is clinically euthyroid, as evidenced by a normal heart rate and complete resolution of palpitations.
Clinical response is an essential first indicator of treatment efficacy and tolerance.
2
Interpret the laboratory findings in the context of recent hyperthyroidism treatment.
Free T4 and total T3 have normalized, indicating adequate disease control, while TSH remains suppressed.
Following prolonged hyperthyroidism, pituitary recovery of TSH production lags significantly (often by months) behind the normalization of peripheral thyroid hormones.
3
Determine the appropriate adjustment to the medication regimen.
The current dose of methimazole should be maintained.
The patient has achieved the therapeutic goal (normalization of T3/T4) without overshooting into hypothyroidism. Adjusting the dose based on TSH at this stage would be inappropriate.

Key Concept

In the initial weeks of treating hyperthyroidism, TSH remains suppressed due to prolonged pituitary suppression; therefore, treatment efficacy and dose adjustments should be based on free T4 and total T3 levels, not TSH.
Estimated Time:1m 0s
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic